What is GW Pharmaceuticals?

GW Pharmaceuticals was founded in 1998 and listed on the AiM, a market of the London Stock Exchange, in June 2001. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes.

GW is a pharmaceutical group developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic conditions. GW has assembled a team of over 100 scientists with extensive experience in developing both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW maintains control over all aspects of the product development process - botanical research, cultivation, extraction, formulation into drug delivery technologies, clinical trials and regulatory affairs. The Group has a broad product portfolio and the Directors have identified certain key markets for its products including Multiple Sclerosis, neuropathic pain, and cancer Pain.

GW’s lead product, Sativex®, received regulatory approval in Canada for the symptomatic relief of neuropathic pain in multiple sclerosis in April 2005. In August 2007, Health Canada approved Sativex® as adjunctive analgesic treatment in patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Both approvals were secured under the Notice of Compliance with Conditions (NOC/c) policy. Sativex® is marketed in Canada exclusively by Bayer Healthcare.